BET bromodomain inhibitors synergize with ATR inhibitors in melanoma

Mostrar otras versiones (1)

Metastatic malignant melanoma continues to be a challenging disease despite clinical translation of the comprehensive understanding of driver mutations and how melanoma cells evade immune attack. In Myc-driven lymphoma, efficacy of epigenetic inhibitors of the bromodomain and extra-terminal domain (...

Descripción completa

Detalles Bibliográficos
Autores principales: Muralidharan, Somsundar Veppil, Einarsdottir, Berglind Osk, Bhadury, Joydeep, Lindberg, Mattias F, Wu, Jin, Campeau, Eric, Bagge, Roger Olofsson, Stierner, Ulrika, Ny, Lars, Nilsson, Lisa M, Nilsson, Jonas A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596569/
https://www.ncbi.nlm.nih.gov/pubmed/28796244
http://dx.doi.org/10.1038/cddis.2017.383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596569/
https://www.ncbi.nlm.nih.gov/pubmed/28796244
http://dx.doi.org/10.1038/cddis.2017.383

Ejemplares similares